| EGPA patients (n = 17) |  | Comparison between EGPA patients with at onset and at remission | CEP patients (n = 12) |  | Comparison between CEP patients with at onset and after an improvement |
---|---|---|---|---|---|---|
 | At onset | At remission | P | At onset | After an improvement | P |
Peripheral blood | ||||||
WBC (/mL) in blood, mean ± 1 SD | 15,150 ± 9,062b,a | 8,655 ± 2,542 | < 0.01a | 9,906 ± 4,637 | 6,928 ± 2,086 | < 0.01b |
Blood eosinophils (/mL), mean ± 1 SD | 7,356 ± 6,293b,** | 142.9 ± 132.7 | < 0.01a | 3,390 ± 3,575 | 585.0 ± 443.0 | < 0.01a |
log IgE RIST in serum | 2.910 ± 0.495 | 0.754 ± 0.259 | < 0.01a | 2.647 ± 0.505 | 0.921 ± 0.445 | < 0.01a |
MPO-ANCA (%) | 41.2c,* | 0 | < 0.05c,* | 0 | 0 | NSc |
PR3-ANCA (%) | 0 | 0 | NSc | 0 | 0 | NSc |
ICAM-1 level in serum (ng/mL) | 531.5 ± 136.4b,* | 392.2 ± 128.3 | < 0.01a | 372.0 ± 259.6 | 343.4 ± 37.3 | NSa |
VCAM-1 level in serum (ng/mL) | 2633.6 ± 4102.7 | 756.5 ± 563.9 | < 0.05a | 651.6 ± 132.0 | 680.2 ± 415.1 | NSa |
VEGF level in serum (pg/mL) | 231.9 ± 169.4 | 388.7 ± 265.3 | < 0.05a | 192.1 ± 99.1 | 104.8 ± 111.0 | NSa |
Percentage of CD4+ T cells producing IL-17 (%) | 8.9 ± 5.2b,** | 0.7 ± 1.8 | < 0.01 | 2.2 ± 2.7 | 1.0 ± 1.8 | NSa |
Pathological findings in colon | ||||||
Necrotizing vasculitis (yes/no) | 0/17 | 0/17 | NSc | 0/12 | N.D | NSc |
Granuloma (yes/no) | 0/17 | 0/17 | NSc | 0/12 | N.D | NSc |
The number of eosinophils in submucosa (/mm2) | 113.0 ± 46.6b,* | 29.5 ± 18.8 | < 0.01a | 81.9 ± 49.3 | N.D |  |
Interval between basement membrane and crypt (/mm) | 7.7 ± 1.3b,** | 5.8 ± 1.2 | < 0.01a | 5.4 ± 1.9 | N.D |  |
Interval between crypt and crypt (/mm) | 5.5 ± 1.0b,** | 3.7 ± 1.7 | < 0.01a | 2.8 ± 1.0 | N.D |  |